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Background: Aortic regurgitation (AR) and stenosis (AS) are common causes of debility and death, preventable by timely valve replacement (AVR). 
However, in pts with normal (nl) left ventricular (LV) performance, objective indications for AVR are based on relatively crude and imprecise measures 
of LV size. Insight into disease pathobiology might sharpen prognostication. Therefore, we sought the relation between myocardial mRNA expression 
(from surgical biopsies) and corresponding plasma proteins, and related both to LV size.
Method: Tru-cut biopsies were obtained from LV free wall in pts with nl LV performance undergoing AVR for isolated, pure AS (n=9), isolated, 
pure AR (n=10), or, as controls, for stable coronary artery disease (CAD) undergoing bypass grafting (n=7). cRNA was labeled to probe Affymetrix 
microarrays (Human Genome U133 Plus 2.0). Plasma (drawn immediately before cardioplegia) was employed for ELISA determination of protein 
concentrations.
Results: TNFSF10 (Tumor Necrosis Factor [ligand] Super Family 10) mRNA was upregulated in AR relative to AS 1.7-fold (p<0.05). IL6 (Interleukin 
6) was upregulated in AR vs CAD (1.8-fold, p<0.05 ). When pts with TNFSF10 concentrations >140 pg/mL (n=4) were excluded from analysis, 
plasma concentrations (mean± standard deviation) for TNFSF10 were AR 83±23 vs AS, 62±10 (p=0.038) and CAD 81±29. TNFSF10 plasma vs 
mRNA concentrations were correlated (r2 = 0.215, p=0.034). Myocardial TNFSF10 mRNA and plasma TNFSF10 also were correlated with LVIDD (r2 
= 0.266, p= 0.020 and r2 = 0.404, p= 0.011). Although plasma IL6 was unrelated to myocardial IL6 mRNA (and thus probably from a non-cardiac 
source), pts with highest plasma TNFSF10 also had among the highest plasma IL6.
Conclusion: Our findings suggest that TNFSF10 plasma protein concentrations reflect myocardial TNFSF10 gene expression and both increase with 
increasing LVIDD. Plasma TNFSF10 protein concentration may provide useful insight into the biological state of the myocardium that could modulate 
prognostic conclusions drawn from LV dilatation magnitude alone. Plasma IL6 concentration may help identify pts with particularly high plasma 
TNFSF10 arising from extramyocardial expression.
